Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Keywords

Gefitinib, Paclitaxel, Carboplatin, Pulmonary adenocarcinoma, Adenocarcinoma

References

No references recorded for this paper.

Cited by

• Personalized medicine in oncology: the future is nowHallas H Ridgeway — 2010
• Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung CancerPablo Campos Palacín — 2010
• Review: Targeted therapies in small cell lung cancer: a reviewBernard Eisenschitz — 2010
• NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.W. J. Rorabaugh — 2011
• SnapShot: non-small cell lung cancer.Rebecca S. Heist, Jeffrey A. Engelman — 2012
• A Prospective PCR-Based Screening for the EML4-ALK Oncogene in Non–Small Cell Lung CancerMaría del Carmen Vázquez Rodríguez — 2012
• Antitumor Effects of a Novel Chromosome Region Maintenance 1 (CRM1) Inhibitor on Non-Small Cell Lung Cancer Cells In Vitro and in Mouse Tumor XenograftsJavier María García López — 2014
• Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case reportS. Peterson, A. Ghiorso — 2014
• Phase I dose-escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumorsMarı́a Cuesta, Pedro Cobo — 2014
• Acquired resistance to mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical modelsMichelle D. Shinn, S. Benson, Anne Marie Watson — 2015
• The BCL-2 family: key mediators of the apoptotic response to targeted anti-cancer therapeuticsChristine Porter — 2015
• TARGETED THERAPY IN CANCERLynn K. Bradshaw — 2015
• Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancerÁlvaro Caballo Trebol — 2015
• Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutationJohnny Nawracaj — 2017
• Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer.Christine Arkinstall — 2018
• Rôle de l’évaluation gériatrique dans le traitement des CBNPC au stade métastatiqueR. Corre — 2012
• Targeted Therapies for Gastric CancerJaclyn Yoong, Michael Michael, Trevor Leong — 2011
• Novel agents in invasive urothelial cancer.Arjun Vasant Balar, Matthew I. Milowsky — 2012
• Tumeurs intra-thoraciques : mutations oncogéniques et problématiques cliniques : prédisposition génétique au cancer broncho-pulmonaire chez le patient non-fumeur : hétérogénéité inter- et intra- tumorale des cancers broncho-pulmonaires : étude génomique intégrative des tumeurs épithéliales du thymusNicolas Girard — 2011
• EGFR突变状态对可手术切除的肺腺癌患者复发及生存的预测价值Yu Dong, Ying Li, Hong Peng — 2013

Related papers

No related papers recorded.